Skip to main content

Day: September 28, 2023

Response to Media Speculation

Written by Customer Service on . Posted in Public Companies.

SYDNEY, Australia, Sept. 27, 2023 (GLOBE NEWSWIRE) — Lithium Power International Limited (ASX: LPI) (“Lithium Power” or “the Company”) refers to recent media speculation regarding discussions between Corporación Nacional del Cobre de Chile (“Codelco”) and Lithium Power about a potential transaction. Lithium Power confirms that it is in discussions with Codelco regarding a potential transaction. However, at this stage, discussions between Lithium Power and Codelco are incomplete and no agreement on terms has been reached. Codelco has been granted due diligence and is continuing to undertake its due diligence investigations. Lithium Power notes that there is no certainty that the discussions with Codelco will lead to consummation of a transaction. Lithium Power will continue to keep the market fully informed, in accordance with its...

Continue reading

SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance

Written by Customer Service on . Posted in Public Companies.

BREXAFEMMECartonBREXAFEMMEBlister PackJERSEY CITY, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. is conducting a voluntary nationwide recall of 2 lots of BREXAFEMME® (ibrexafungerp tablets) to the consumer level in the US market due to potential cross contamination with a non-antibacterial ß-lactam drug substance in the ibrexafungerp citrate used to manufacture the BREXAFEMME® tablets. During a review of manufacturing equipment and cleaning activities at a supplier, SCYNEXIS was made aware of potential cross-contamination risk with a non-antibacterial beta-lactam drug substance. This press release provides additional details on the voluntary product recall recently disclosed by SCYNEXIS. Risk Statement: The potential cross contamination with a non-antibacterial beta-lactam drug substance could lead to...

Continue reading

Update in relation to merger with Livent Corporation

Written by Customer Service on . Posted in Mergers And Acquisitions.

BRISBANE, Australia, Sept. 27, 2023 (GLOBE NEWSWIRE) — Allkem Limited (ASX: AKE, “Allkem” or the “Company”) provides an update in relation to the proposed merger of equals between Allkem and Livent Corporation (“Livent”) announced to ASX on 10 May 2023 (“Transaction”). Transaction update Allkem is pleased to provide the following update on the progress of the Transaction:Further to Allkem’s announcement on 24 July 2023, Allkem Livent plc1 (“New TopCo”) has today filed with the U.S. Securities and Exchange Commission (“SEC”) Amendment No. 1 and Amendment No. 2 to the preliminary registration statement on Form S-4 that contains a proxy statement/prospectus (together the “Revised Preliminary Form S-4”) All competition and foreign investment approvals are expected to be received prior to the proposed closing of the Transaction Subject...

Continue reading

Ocugen to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference

Written by Customer Service on . Posted in Public Companies.

MALVERN, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder and Dr. Huma Qamar, MPH, CMI, Head of Clinical Development and Medical Affairs will participate in an in-person fireside chat moderated by Daniil Gataulin, PhD, Senior Biotech Research Analyst at the Chardan 7th Annual Genetic Medicines Conference being held October 2-3, 2023 in NYC. Details regarding the fireside chat are as follows: Date: October 2, 2023 Location: Westin Grand Central, New York, NY Time: 1:30 p.m. ET Webcast Link: https://ir.ocugen.com/events/event-details/chardans-7th-annual-genetic-medicines-conference In...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.